Latest News

Is Metformin An Unexpected Ally Against Long COVID?


 

TOPLINE:

Metformin use in adults with type 2 diabetes (T2D) is associated with a slightly lower incidence of long COVID and death within 180 days after SARS-CoV-2 infection.

METHODOLOGY:

  • Previous studies have shown that metformin use before and during SARS-CoV-2 infection reduces severe COVID-19 and postacute sequelae of SARS-CoV-2 (PASC), also referred to as long COVID, in adults.
  • A retrospective cohort analysis was conducted to evaluate the association between metformin use before and during SARS-CoV-2 infection and the subsequent incidence of PASC.
  • Researchers used data from the National COVID Cohort Collaborative (N3C) and National Patient-Centered Clinical Research Network (PCORnet) electronic health record (EHR) databases to identify adults (age, ≥ 21 years) with T2D prescribed a diabetes medication within the past 12 months.
  • Participants were categorized into those using metformin (metformin group) and those using other noninsulin diabetes medications such as sulfonylureas, dipeptidyl peptidase-4 inhibitors, or thiazolidinediones (the comparator group); those who used glucagon-like peptide 1 receptor agonists or sodium-glucose cotransporter-2 inhibitors were excluded.
  • The primary outcome was the incidence of PASC or death within 180 days after SARS-CoV-2 infection, defined using International Classification of Diseases U09.9 diagnosis code and/or computable phenotype defined by a predicted probability of > 75% for PASC using a machine learning model trained on patients diagnosed using U09.9 (PASC computable phenotype).

TAKEAWAY:

  • Researchers identified 51,385 and 37,947 participants from the N3C and PCORnet datasets, respectively.
  • Metformin use was associated with a 21% lower risk for death or PASC using the U09.9 diagnosis code (P < .001) and a 15% lower risk using the PASC computable phenotype (P < .001) in the N3C dataset than non-metformin use.
  • In the PCORnet dataset, the risk for death or PASC was 13% lower using the U09.9 diagnosis code (P = .08) with metformin use vs non-metformin use, whereas the risk did not differ significantly between the groups when using the PASC computable phenotype (P = .58).
  • The incidence of PASC using the U09.9 diagnosis code for the metformin and comparator groups was similar between the two datasets (1.6% and 2.0% in N3C and 2.2 and 2.6% in PCORnet, respectively).
  • However, when using the computable phenotype, the incidence rates of PASC for the metformin and comparator groups were 4.8% and 5.2% in N3C and 25.2% and 24.2% in PCORnet, respectively.

IN PRACTICE:

“The incidence of PASC was lower when defined by [International Classification of Diseases] code, compared with a computable phenotype in both databases,” the authors wrote. “This may reflect the challenges of clinical care for adults needing chronic medication management and the likelihood of those adults receiving a formal PASC diagnosis.”

SOURCE:

The study was led by Steven G. Johnson, PhD, Institute for Health Informatics, University of Minnesota, Minneapolis. It was published online in Diabetes Care.

Pages

Recommended Reading

For Some MDs, Long COVID Burnout Is a New Reality
MDedge Infectious Disease
4 Years In, a Sobering Look at Long COVID Progress
MDedge Infectious Disease
The Push to Get More People Into Long COVID Studies
MDedge Infectious Disease
MDs’ One-Word Summary of Long COVID Progress: ‘Frustration’
MDedge Infectious Disease
National Academies Issue New Broad Definition of Long COVID
MDedge Infectious Disease
Long COVID Can’t Be Solved Until We Decide What It Is
MDedge Infectious Disease
Cold or Flu Virus May Trigger Relapse of Long COVID
MDedge Infectious Disease
Almost 10% of Infected Pregnant People Develop Long COVID
MDedge Infectious Disease
Disruptive Sleep Linked to Increased Susceptibility to COVID-19
MDedge Infectious Disease
Paxlovid, Supplements May Improve Long COVID Symptoms
MDedge Infectious Disease